Media stories about RadNet (NASDAQ:RDNT) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RadNet earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.1889688022648 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

RadNet (NASDAQ:RDNT) traded up 0.63% on Friday, hitting $7.95. The company’s stock had a trading volume of 108,173 shares. The firm has a market cap of $375.76 million, a price-to-earnings ratio of 41.84 and a beta of 1.01. RadNet has a 12 month low of $5.25 and a 12 month high of $8.70. The firm has a 50 day moving average of $7.72 and a 200 day moving average of $6.68.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.07. The firm had revenue of $230 million for the quarter, compared to analyst estimates of $230.32 million. RadNet had a net margin of 1.04% and a return on equity of 19.98%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.09 earnings per share. Equities research analysts forecast that RadNet will post $0.29 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded RadNet from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact RadNet (NASDAQ:RDNT) Stock Price” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-radnet-nasdaqrdnt-stock-price.html.

In other news, insider Norman R. Hames sold 5,000 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $7.71, for a total transaction of $38,550.00. Following the sale, the insider now directly owns 422,131 shares of the company’s stock, valued at $3,254,630.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Norman R. Hames sold 39,072 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $7.22, for a total transaction of $282,099.84. Following the sale, the insider now directly owns 563,703 shares in the company, valued at $4,069,935.66. The disclosure for this sale can be found here. Insiders have sold 262,838 shares of company stock worth $1,955,532 over the last three months. Corporate insiders own 9.36% of the company’s stock.

About RadNet

RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.